07:00 , Sep 3, 2012 |  BC Week In Review  |  Clinical News

Bedoradrine: Preliminary Phase Ib data

Preliminary data from the double-blind, placebo-controlled, U.S. Phase Ib MN-221-CL-012 trial in 25 patients with stable, moderate to severe COPD showed that 6 injections of 1,200 µg IV MN-221 over 4 days produced no clinically...
07:00 , Jul 2, 2012 |  BioCentury  |  Finance

2Q Stock Wrap-Up: Magic in mid-caps

Mid-caps performed best last quarter, with four companies gaining more than 50%. Other segments largely held on to their 1Q gains, except for companies valued below $200 million, which fell 15% in the quarter and...
07:00 , May 28, 2012 |  BC Week In Review  |  Clinical News

Bedoradrine: Preliminary Phase IIb data

Preliminary data from 144 evaluable patients with acute exacerbations of asthma in the double-blind, U.S. Phase IIb MN-221-CL-007 trial showed that a 1-hour IV infusion with 1,200 µg MN-221 as an adjunct to standard of...
07:00 , May 28, 2012 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 5/25 cls Affymax Inc. (NASDAQ:AFFY) MLV Ed Arce Price target Buy 8% $14.07 Arce raised his target to $21 from $12 after Affymax and...
07:00 , May 28, 2012 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Furiex Pharmaceuticals Inc. (NASDAQ:FURX) gained $3.34 (21%) to $19.10 last week after EMA accepted for review an MAA from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) for alogliptin to treat Type II diabetes. The acceptance...
01:19 , May 25, 2012 |  BC Extra  |  Clinical News

MediciNova falls on asthma data

MediciNova Inc. (NASDAQ:MNOV; Osaka:4875) fell $1.18 (43%) to $1.57 on Thursday after MN-221 as an adjunct to standard of care missed the primary endpoint of improving percent predicted forced expiratory volume in one second (FEV1)...
07:00 , Mar 26, 2012 |  BC Week In Review  |  Clinical News

Bedoradrine: Completed Phase II enrollment

MediciNova completed enrollment of 176 patients in a double-blind, placebo-controlled, U.S. Phase II (MN-221-CL-007) trial evaluating 1,200 µg IV MN-221. The company has exclusive, ex-Japanese rights to MN-221 from Kissei. MediciNova Inc. (NASDAQ:MNOV; Osaka:4875), San...
08:00 , Nov 7, 2011 |  BC Week In Review  |  Clinical News

Bedoradrine: Phase Ib start

By year end, MediciNova will begin a placebo-controlled Phase Ib trial to evaluate multiple doses of 1,200 µg IV MN-221 in patients with moderate to severe COPD. MediciNova has ex-Japanese rights to the compound from...
07:00 , Oct 24, 2011 |  BC Week In Review  |  Company News

MediciNova, Kissei Pharmaceutical deal

Kissei will pay MediciNova $2.5 million to support development of MN-221 to treat acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). MediciNova expects top-line data from a Phase IIb trial of MN-221 in...
07:00 , Jul 11, 2011 |  BC Week In Review  |  Company News

MediciNova, Zhejiang Medicine deal

MediciNova and Zhejiang finalized a deal and formed a JV to develop and commercialize MediciNova's MN-221 in China. The JV, named Zhejiang Sunmy Medicine Biotechnology Corp. Ltd., plans to submit an IND in China by...